WallStreetZenWallStreetZen

NASDAQ: CRVS
Corvus Pharmaceuticals Inc Stock

$2.00-0.05 (-2.44%)
Updated Jul 15, 2024
CRVS Price
$2.00
Fair Value Price
$0.23
Market Cap
$125.10M
52 Week Low
$1.05
52 Week High
$2.86
P/E
-3.92x
P/B
3.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.2
Operating Cash Flow
-$21M
Beta
0.91
Next Earnings
Aug 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CRVS Overview

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRVS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CRVS ($2.00) is overvalued by 754.09% relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRVS ($2.00) is not significantly undervalued (754.09%) relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRVS due diligence checks available for Premium users.

Be the first to know about important CRVS news, forecast changes, insider trades & much more!

CRVS News

Valuation

CRVS fair value

Fair Value of CRVS stock based on Discounted Cash Flow (DCF)
Price
$2.00
Fair Value
$0.23
Overvalued by
754.09%
CRVS ($2.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRVS ($2.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CRVS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.92x
Industry
-20.45x
Market
31.91x

CRVS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.75x
Industry
6.46x
CRVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CRVS's financial health

Profit margin

Revenue
$0.0
Net Income
-$5.7M
Profit Margin
0%
CRVS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$40.1M
Liabilities
$6.7M
Debt to equity
0.2
CRVS's short-term assets ($22.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRVS's short-term assets ($22.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRVS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CRVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.2M
Investing
-$7.0k
Financing
$0.0
CRVS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CRVS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CRVS$125.10M-2.44%-3.92x3.75x
RAPT$124.61M+4.08%-1.16x0.95x
HOWL$124.28M+6.32%-2.62x1.06x
TELO$122.58M+0.24%N/A40.64x
IMUX$122.51M-1.45%-0.74x1.47x

Corvus Pharmaceuticals Stock FAQ

What is Corvus Pharmaceuticals's quote symbol?

(NASDAQ: CRVS) Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol CRVS. Corvus Pharmaceuticals stock quotes can also be displayed as NASDAQ: CRVS.

If you're new to stock investing, here's how to buy Corvus Pharmaceuticals stock.

What is the 52 week high and low for Corvus Pharmaceuticals (NASDAQ: CRVS)?

(NASDAQ: CRVS) Corvus Pharmaceuticals's 52-week high was $2.86, and its 52-week low was $1.05. It is currently -30.07% from its 52-week high and 90.48% from its 52-week low.

How much is Corvus Pharmaceuticals stock worth today?

(NASDAQ: CRVS) Corvus Pharmaceuticals currently has 62,551,281 outstanding shares. With Corvus Pharmaceuticals stock trading at $2.00 per share, the total value of Corvus Pharmaceuticals stock (market capitalization) is $125.10M.

Corvus Pharmaceuticals stock was originally listed at a price of $14.25 in Mar 23, 2016. If you had invested in Corvus Pharmaceuticals stock at $14.25, your return over the last 8 years would have been -85.96%, for an annualized return of -21.76% (not including any dividends or dividend reinvestments).

How much is Corvus Pharmaceuticals's stock price per share?

(NASDAQ: CRVS) Corvus Pharmaceuticals stock price per share is $2.00 today (as of Jul 15, 2024).

What is Corvus Pharmaceuticals's Market Cap?

(NASDAQ: CRVS) Corvus Pharmaceuticals's market cap is $125.10M, as of Jul 16, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Corvus Pharmaceuticals's market cap is calculated by multiplying CRVS's current stock price of $2.00 by CRVS's total outstanding shares of 62,551,281.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.